ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Perturbed Microbial Ecology in Myasthenia Gravis: Evidence from the Gut Microbiome and Fecal Metabolome.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Gut microbiota and neuromuscular disorders: a comprehensive review.Arquivos de neuro-psiquiatria · 2026Review
- The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026Review
- EngineeredAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Oral microbiota and serum metabolomics features in newly diagnosed anti-AchR antibody-positive myasthenia gravis patients.Frontiers in immunology · 2026Article
- Disruption of intestinal barrier and immune homeostasis links gut microbiota dysbiosis to aggravated experimental autoimmune myasthenia gravis.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Dynamic alterations of depressive-like behaviors, gut microbiome, and fecal metabolome in social defeat stress mice.Translational psychiatry · 2025Article
- Myasthenia gravis in 2025: five new things and four hopes for the future.Journal of neurology · 2025Review
- Gut microbial profiles of patients with optic neuritis or myasthenia gravis.The Journal of international medical research · 2025Article
- Explainable machine learning model for identifying key gut microbes and metabolites biomarkers associated with myasthenia gravis.Computational and structural biotechnology journal · 2024Article
- Gut microbiota-derived butyrate restores impaired regulatory T cells in patients with AChR myasthenia gravis via mTOR-mediated autophagy.Cell communication and signaling : CCS · 2024Article
- Article
- Mendelian randomization study revealed a gut microbiota-neuromuscular junction axis in myasthenia gravis.Scientific reports · 2024Article
- Mendelian randomization analyses of known and suspected risk factors and biomarkers for myasthenia gravis overall and by subtypes.BMC neurology · 2024Article
- Review
- Causal relationship between gut microbiota and myasthenia gravis: a two-sample Mendelian randomization study.Frontiers in neurology · 2024Article
- Causal relationship between gut microbiota and myasthenia gravis: a bidirectional mendelian randomization study.Cell & bioscience · 2023Article
- Gut microbiota in muscular atrophy development, progression, and treatment: New therapeutic targets and opportunities.Innovation (Cambridge (Mass.)) · 2023Review
- Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4 + T cells and altering gut microbiota.Chinese medicine · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is a devastating acquired autoimmune disease. Emerging evidence indicates that the gut microbiome plays a key role in maintaining immune system homeostasis. This work reports that MG is characterized by decreased α-phylogenetic diversity, and significantly disturbed gut microbiome and fecal metabolome. The altered gut microbial composition is associated with fecal metabolome changes, with 38.75% of altered bacterial operational taxonomic units showing significant correlations with a range of metabolite biomarkers. Some microbes are particularly linked with MG severity. Moreover, a combination of microbial makers and their correlated metabolites enable discriminating MG from healthy controls (HCs) with 100% accuracy. To investigate whether disturbed gut mcirobiome might contribute to the onset of MG, germ-free (GF) mice are initially colonized with MG microbiota (MMb) or healthy microbiota (HMb), and then immunized in a classic mouse model of MG. The MMb mice demonstrate substantially impaired locomotion ability compared with the HMb mice. This effect could be reversed by cocolonizing GF mice with both MMb and HMb. The MMb mice also exhibit similar disturbances of fecal metabolic pathways as found in MG. Together these data demonstrate disturbances in microbiome composition and activity that are likely to be relevant to the pathogenesis of MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.